The study demonstrated that 124I-trametinib was taken up at higher rates in BRAF and KRAS mutant cancers compared to wild type and that peak tumor concentrations in the tumor occurred at approximately 24–48 hours, compared to peak uptake in the skin and gastrointestinal tract which occurred between 6 and 24 hours. The gene discussed is KRAS; the disease is neoplasm.